Prospective assessment of circulating tumor DNA in patients with metastatic uveal melanoma treated with tebentafusp
Manuel Rodrigues(Inserm), Shufang Renault(Université Paris Sciences et Lettres), François‐Clément Bidard(Inserm), Aurore Rampanou(Université Paris Sciences et Lettres), Nathalie Cassoux(Institut Curie), Vincent Servois(Université Paris Sciences et Lettres), Pascale Mariani(Université Paris Sciences et Lettres), Thomas Ryckewaert(Centre Oscar Lambret), Marc Pracht(Canadian Partnership Against Cancer), Marc‐Henri Stern(Université Paris Sciences et Lettres), Anne Vincent‐Salomon(Université Paris Sciences et Lettres), Alexandre Houy(Inserm), Léah Mailly-Giacchetti(Inserm), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Sergio Roman‐Roman(Université Paris Sciences et Lettres), Gaëlle Pierron(Institut Curie), Jean‐Emmanuel Kurtz(Université de Strasbourg), Toulsie Ramtohul(Université Paris Sciences et Lettres), José Luis Ruiz Sandoval(Inserm), Sophie Piperno‐Neumann(Institut Curie)
Cited by 30
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k